Cargando…

Minimal cross-over between mutations associated with Omicron variant of SARS-CoV-2 and CD8+ T cell epitopes identified in COVID-19 convalescent individuals

Mostrar otras versiones (1)

There is a growing concern that ongoing evolution of SARS-CoV-2 could lead to variants of concern (VOC) that are capable of avoiding some or all of the multi-faceted immune response generated by both prior infection or vaccination, with the recently described B.1.1.529 (Omicron) VOC being of particu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Redd, Andrew D, Nardin, Alessandra, Kared, Hassen, Bloch, Evan M, Abel, Brian, Pekosz, Andrew, Laeyendecker, Oliver, Fehlings, Michael, Quinn, Thomas C, Tobian, Aaron AR
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8669839/ https://www.ncbi.nlm.nih.gov/pubmed/34909772 http://dx.doi.org/10.1101/2021.12.06.471446

Ejemplares similares

Minimal Crossover between Mutations Associated with Omicron Variant of SARS-CoV-2 and CD8(+) T-Cell Epitopes Identified in COVID-19 Convalescent Individuals
por: Redd, Andrew D., et al.
Publicado: (2022)

CD8+ T cell responses in COVID-19 convalescent individuals target conserved epitopes from multiple prominent SARS-CoV-2 circulating variants
por: Redd, Andrew D, et al.
Publicado: (2021)

CD8+ T-Cell Responses in COVID-19 Convalescent Individuals Target Conserved Epitopes From Multiple Prominent SARS-CoV-2 Circulating Variants
por: Redd, Andrew D, et al.
Publicado: (2021)

CD8+ T cell responses in convalescent COVID-19 individuals target epitopes from the entire SARS-CoV-2 proteome and show kinetics of early differentiation
por: Kared, Hassen, et al.
Publicado: (2020)

LB-18. Broad and Prevalent SARS-CoV-2 CD8+ T Cell Response in Recovered COVID-19 Individuals Demonstrates Kinetics of Early Differentiation
por: Kared, Hassen, et al.
Publicado: (2020)

Cytokine and Chemokine Levels in Coronavirus Disease 2019 Convalescent Plasma
por: Bonny, Tania S, et al.
Publicado: (2020)

Differential antibody production by symptomatology in SARS-CoV-2 convalescent individuals
por: Saraf, Sharada, et al.
Publicado: (2022)

Absence of pathogenic viruses in COVID‐19 convalescent plasma
por: Kandathil, Abraham J., et al.
Publicado: (2022)

Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population
por: Klein, Sabra, et al.
Publicado: (2020)

Differential antibody production by symptomatology in SARS-CoV-2 convalescent individuals
por: Saraf, Sharada, et al.
Publicado: (2022)

Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma
por: Natarajan, Harini, et al.
Publicado: (2021)

SARS-CoV-2 antibody signatures robustly predict diverse antiviral functions relevant for convalescent plasma therapy
por: Natarajan, Harini, et al.
Publicado: (2020)

Antibody responses to endemic coronaviruses modulate COVID-19 convalescent plasma functionality
por: Morgenlander, William, et al.
Publicado: (2020)

Promoting access to COVID-19 convalescent plasma in low- and middle-income countries
por: Bloch, Evan M., et al.
Publicado: (2021)

Earlier the better: convalescent plasma
por: Tobian, Aaron A.R., et al.
Publicado: (2020)

SARS-CoV-2 Antibody Avidity Responses in COVID-19 Patients and Convalescent Plasma Donors
por: Benner, Sarah E, et al.
Publicado: (2020)

Coronavirus Disease 2019 Convalescent Plasma and the Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Titer
por: Bloch, Evan M, et al.
Publicado: (2021)

Demographic and clinical correlates of acute and convalescent SARS-CoV-2 infection among patients of a U.S. emergency department
por: Laeyendecker, Oliver, et al.
Publicado: (2021)

Spike-protein proteolytic antibodies in COVID-19 convalescent plasma contribute to SARS-CoV-2 neutralization
por: McConnell, Scott A., et al.
Publicado: (2023)

Comparative performance of multiplex salivary and commercially available serologic assays to detect SARS-CoV-2 IgG and neutralization titers
por: Heaney, Christopher D., et al.
Publicado: (2021)

COVID-19 convalescent plasma
por: Tobian, Aaron A. R., et al.
Publicado: (2022)

Comparative performance of multiplex salivary and commercially available serologic assays to detect SARS-CoV-2 IgG and neutralization titers
por: Heaney, Christopher D., et al.
Publicado: (2021)

High Viral Specific Antibody Convalescent Plasma Effectively Neutralizes SARS-CoV-2 Variants of Concern
por: Li, Maggie, et al.
Publicado: (2022)

A Hemagglutination-Based Semiquantitative Test for Point-of-Care Determination of SARS-CoV-2 Antibody Levels
por: Kruse, Robert L., et al.
Publicado: (2021)

Sequential dosing of convalescent COVID-19 plasma with significant temporal clinical improvements in a persistently SARS-COV-2 positive patient
por: Mirihagalle, Noupama, et al.
Publicado: (2021)

Differentiation of SARS-CoV-2 naturally infected and vaccinated individuals in an inner-city emergency department
por: Beck, Evan J, et al.
Publicado: (2021)

Comparative performance of five commercially available serologic assays to detect antibodies to SARS-CoV-2 and identify individuals with high neutralizing titers
por: Patel, Eshan U., et al.
Publicado: (2020)

Convalescent plasma to treat COVID-19
por: Bloch, Evan M.
Publicado: (2020)

The feasibility of multiple units of convalescent plasma in mechanically ventilated patients with COVID-19: A pilot study
por: Merin, Noah M., et al.
Publicado: (2022)

Antibody Attributes that Predict the Neutralization and Effector Function of Polyclonal Responses to SARS-CoV-2
por: Natarajan, Harini, et al.
Publicado: (2021)

Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern
por: Li, Maggie, et al.
Publicado: (2022)

A Fourth Dose of COVID-19 Vaccine Does Not Induce Neutralization of the Omicron Variant Among Solid Organ Transplant Recipients With Suboptimal Vaccine Response
por: Karaba, Andrew H., et al.
Publicado: (2022)

Early Outpatient Treatment for Covid-19 with Convalescent Plasma
por: Sullivan, David J., et al.
Publicado: (2022)

Endemic Human Coronavirus Antibody Levels Are Unchanged after Convalescent or Control Plasma Transfusion for Early Outpatient COVID-19 Treatment
por: Karaba, Andrew H., et al.
Publicado: (2023)

Pharmacokinetics of high-titer anti–SARS-CoV-2 human convalescent plasma in high-risk children
por: Gordon, Oren, et al.
Publicado: (2022)

Comparative Performance of Five Commercially Available Serologic Assays To Detect Antibodies to SARS-CoV-2 and Identify Individuals with High Neutralizing Titers
por: Patel, Eshan U., et al.
Publicado: (2021)

Comirnaty-Elicited and Convalescent Sera Recognize Different Spike Epitopes
por: Hein, Sascha, et al.
Publicado: (2021)

Differentiation of Individuals Previously Infected with and Vaccinated for SARS-CoV-2 in an Inner-City Emergency Department
por: Beck, Evan J., et al.
Publicado: (2022)

SARS-CoV-2 mRNA vaccination elicits broad and potent Fc effector functions to VOCs in vulnerable populations
por: Hederman, Andrew P., et al.
Publicado: (2022)

Neutralizing activity and 3-month durability of tixagevimab and cilgavimab prophylaxis against Omicron sublineages in transplant recipients
por: Karaba, Andrew H., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0n338rblhmkjofav8ou9eiqone